Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 4:13:832732.
doi: 10.3389/fphar.2022.832732. eCollection 2022.

The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases

Jianjun Gao  1 , Zhaoyan Gu  2   3
Affiliations
Review

The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases

Jianjun Gao et al. Front Pharmacol. .

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. Accumulating evidence suggests that PPARs may play an important role in the pathogenesis of kidney disease. All three members of the PPAR subfamily, PPARα, PPARβ/δ, and PPARγ, have been implicated in many renal pathophysiological conditions, including acute kidney injury, diabetic nephropathy, and chronic kidney disease, among others. Emerging data suggest that PPARs may be potential therapeutic targets for renal disease. This article reviews the physiological roles of PPARs in the kidney and discusses the therapeutic utility of PPAR agonists in the treatment of kidney disease.

Keywords: acute kidney injury; chronic kidney disease; diabetic nephropathy; kidney disease; peroxisome proliferator-activated receptors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Structure and molecular mechanism of action of peroxisome proliferator-activated receptors.
See this image and copyright information in PMC

References

    1. Arany Z., He H., Lin J., Hoyer K., Handschin C., Toka O., et al. (2005). Transcriptional Coactivator PGC-1 Alpha Controls the Energy State and Contractile Function of Cardiac Muscle. Cell Metab 1, 259–271. 10.1016/j.cmet.2005.03.002 - DOI - PubMed
    1. Arora M. K., Reddy K., Balakumar P. (2010). The Low Dose Combination of Fenofibrate and Rosiglitazone Halts the Progression of Diabetes-Induced Experimental Nephropathy. Eur. J. Pharmacol. 636, 137–144. 10.1016/j.ejphar.2010.03.002 - DOI - PubMed
    1. Bae E. H., Kim I. J., Ma S. K., Kim S. W. (2010). Rosiglitazone Prevents the Progression of Renal Injury in DOCA-Salt Hypertensive Rats. Hypertens. Res. 33, 255–262. 10.1038/hr.2009.217 - DOI - PubMed
    1. Bakris G., Viberti G., Weston W. M., Heise M., Porter L. E., Freed M. I. (2003). Rosiglitazone Reduces Urinary Albumin Excretion in Type II Diabetes. J. Hum. Hypertens. 17, 7–12. 10.1038/sj.jhh.1001444 - DOI - PubMed
    1. Baud L., Letavernier E. (2007). PPARalpha Contributes to Tubular protection. J. Am. Soc. Nephrol. 18, 3017–3018. 10.1681/ASN.2007091036 - DOI - PubMed

LinkOut - more resources